Works matching IS 20406207 AND DT 2018 AND VI 9 AND IP 4
Results: 2
Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 4, p. 89, doi. 10.1177/2040620718761777
- By:
- Publication type:
- Article
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.
- Published in:
- Therapeutic Advances in Hematology, 2018, v. 9, n. 4, p. 81, doi. 10.1177/2040620718759249
- By:
- Publication type:
- Article